Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 12/20 | 0.79 |
| ▸ | CCR1 | P32246 | 4/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CCR4 | P51679 | 1/20 | 0.56 |
| ▸ | CCR5 | P51681 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | ACLY | P53396 | 5/20 | 0.55 |
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5665013 | 1.00 | CCR2 (0.79) | CCR2CCR1MEN1GAAKMT2A | |
| SCHEMBL5667420 | 0.93 | CCR2 (0.86) | CCR2CCR1MEN1GAAKMT2A | |
| Diphenylmethanol SCHEMBL8075173 | 0.93 | CCR2 (0.70) | CCR2CCR1MEN1GAAKMT2A | |
| SCHEMBL5666650 | 0.92 | CCR2 (0.88) | CCR2CCR1MEN1GAAKMT2A | |
| SCHEMBL5666146 | 0.92 | CCR2 (0.67) | CCR2CCR1MEN1GAAKMT2A | |
| SCHEMBL5664918 | 0.91 | CCR2 (0.66) | CCR2CCR1MEN1GAAKMT2A | |
| SCHEMBL5666963 | 0.91 | CCR2 (0.66) | CCR2CCR1MEN1GAAKMT2A | |
| SCHEMBL5665401 | 0.90 | CCR2 (0.85) | CCR2CCR1MEN1GAAKMT2A | |
| SCHEMBL5664916 | 0.89 | CCR2 (0.81) | CCR2CCR1MEN1GAAKMT2A | |
| SCHEMBL5665185 | 0.89 | CCR2 (1.00) | CCR2CCR1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217379-A1 | DRUG TREATMENT FOR MACULAR DEGENERATION | UNIVERSITY OF ROCHESTER (US) | 2025-10-16 | — | — | WO | claimed |
| WO-2024073476-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER BY REDUCING THE EXPRESSION AND/OR ACTIVITY OF PLA2G10 | YALE UNIVERSITY (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2025217379-A1 | DRUG TREATMENT FOR MACULAR DEGENERATION | UNIVERSITY OF ROCHESTER (US) | 2025-10-16 | — | — | WO | disclosed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | OPHIREX, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC (US) | 2025-04-15 | — | — | US | disclosed |
| EP-3448378-B1 | PLA2 AND HMG-COA INHIBITORS FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSING HEMOLYSIS, CEREBRAL EDEMA, AND ACUTE KIDNEY INJURY | OPHIREX INC (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024073476-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER BY REDUCING THE EXPRESSION AND/OR ACTIVITY OF PLA2G10 | YALE UNIVERSITY (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-116585306-A | PLA2 inhibitors for immediate treatment of hymenoptera toxicity and other conditions due to histamine release | 奥菲瑞克斯股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-109562098-B | PLA2 inhibitors for immediate treatment of hymenoptera toxicity and other conditions due to histamine release | 奥菲瑞克斯股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274691-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | CCR2 4080/4885CCR1 3160/4885MEN1 2353/4885 |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | PLA2G4A, PLA2G12A, PLA2G6 | CCR2 3867/4885CCR1 2333/4885MEN1 1673/4885 |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | PLA2G12A, PLA2G2D, PLAAT2 | CCR2 4373/4885CCR1 4639/4885MEN1 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.